Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada


CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today issued a presentation on Centurion BioPharma Corporation's ("Centurion BioPharma") plans for a world-class cancer center in Las Vegas, Nevada. Centurion BioPharma is a private wholly-owned subsidiary that focuses on advancing the Company's proprietary, albumin binding ultra-high potency LADRtm (Linker-Activated Drug Release) oncology drug candidates and ACDx diagnostic.

The presentation, which can be found here, highlights how the planned center would:

Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx and Executive Chairman of Centurion BioPharma, commented:

"At CytRx and Centurion BioPharma, we believe establishing a best-in-class healthcare center in the city of Las Vegas can provide advanced cancer care and research for patients, establish Las Vegas as an important hub for further groundbreaking treatments and assist in the development of Centurion BioPharma's LADRtm technology. Over the last three years, Centurion BioPharma has made critical strides in the development and diagnostics of its therapies. A combination immunotherapy including aldoxorubicin, which was developed by the Centurion BioPharma research team, was recently proven successful in a Phase 2 trial for advanced metastatic pancreatic cancer. We believe that establishing a major cancer center in Las Vegas ? which we aim to complete with philanthropic support ? will enable Centurion BioPharma to continue its important scientific research and pursue transformational treatment programs."

About Centurion BioPharma Corporation

CytRx's wholly owned subsidiary, Centurion BioPharma Corporation, is focused on the development of personalized medicine that is designed to transform solid tumor treatment. This transformational strategy combines a portfolio of novel, anti-cancer drug candidates that employ LADRtm (Linker Activated Drug Release) technology, a discovery engine designed to leverage Centurion's expertise in albumin biology and linker technology for the development of a new class of breakthrough anti-cancer therapies with a unique albumin companion diagnostic (ACDx) that can help identify patients who are most likely to benefit from treatment with the LADRtm-derived therapies. A critical element of the LADRtm platform is its ability to bind anti-cancer molecules to circulating albumin, the most ubiquitous protein in human blood plasma, and then to release the highly potent cytotoxic payload at the tumor site. This technology allows for the delivery of higher doses of drug directly to the tumor, while avoiding much of the off-target toxicity observed with the parent molecules. Centurion BioPharma Corporation's website is www.centurionbiopharma.com.

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx's most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx's drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation's website is www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to the ability of ImmunityBio, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of ImmunityBio, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from ImmunityBio, Inc.; Centurion BioPharma Corporation's ability to develop new ultra-high potency drug candidates based on its LADRtm technology platform; our ability to attract potential licensees; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


These press releases may also interest you

at 10:35
Zapata Computing, Inc. ("Zapata AI"), the Industrial Generative AI software company developing solutions to solve enterprises' most difficult, industrial-scale problems, announced today that it has completed its business combination with Andretti...

at 10:30
Youth Enrichment Brands ("YEB"), the nation's leading youth activities platform offering camps, leagues, classes, schools and other programs, announced today the appointment of Dustin Bertram as its new Chief Financial Officer ("CFO")....

at 10:30
The "Consumer Brain-Computer Interface: Market and Product Development Trends" report has been added to  ResearchAndMarkets.com's offering. This report focuses on consumer BCI products, analyzing the technological developments and application areas...

at 10:30
Yiwugo.com, the official website of the Yiwu Commodity Market, is the largest commodity wholesale market in the world. In recent years, there has been a remarkable resurgence in the popularity of Hanfu, the traditional attire of the Chinese nation,...

at 10:29
Integrity Marketing Group, LLC ("Integrity"), one of the leading independent distributors of life, health and wealth products, today announced that Integrity Co-Founder and CEO Bryan W. Adams has been recognized as a top CEO for large companies in...

at 10:28
On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023. In 2023, Broncus Medical earned product sales of US$12.41 million, an increase of 32% compared to the previous year. Of which, total revenue...



News published on and distributed by: